Autosomal Recessive Osteopetrosis Type 6 (OPTB6) Caused by PLEKHM1 Mutations

Autosomal recessive osteopetrosis type 6 is a very rare inherited bone disease caused by harmful changes (variants) in the PLEKHM1 gene. In osteopetrosis, bone becomes abnormally dense but brittle because the bone-removing cells (osteoclasts) cannot resorb bone normally; this leads to narrow bone marrow? spaces, anemia?, low platelets, nerve compression, fractures, and growth problems. PLEKHM1 helps osteoclasts manage internal “traffic” of vesicles needed for bone resorption; when it fails, bone turnover stalls. Different genes can cause different severities of osteopetrosis; PLEKHM1-related disease ranges from mild? to more serious, and is confirmed by genetic? testing. Clinically, OPTB6 is described as an autosomal recessive (both copies faulty) form; some reports note mild courses, while others describe cytopenias and hepatosplenomegaly, showing variability. monarchinitiative.org+4BioMed Central+4NCBI+4

PLEKHM1 encodes a protein that coordinates vesicle movement and autophagy pathways in osteoclasts, processes required to form the ruffled border and resorb bone. Animal models (rat, mouse) and human reports support that loss of PLEKHM1 function impairs osteoclast activity, producing the osteopetrosis picture on X-rays. A curated ClinGen evaluation currently classifies PLEKHM1–OPTB6 gene-disease validity as “Moderate?” (reflecting rarity but consistent biology). ScienceDirect+2repository.uantwerpen.be+2

although osteopetrosis can be very severe? in some genes, PLEKHM1-related osteopetrosis often ranges from mild to intermediate, and a few patients improve with age. this means some children show dense bones early in life, but the signs can lessen later. however, severity varies. NCBI

Other names

• OPTB6 (osteopetrosis, autosomal recessive 6)

• PLEKHM1-related autosomal recessive osteopetrosis

• AR osteopetrosis due to PLEKHM1

• Autosomal recessive osteopetrosis 6 (MONDO:0012679)
  all these labels point to the same condition caused by PLEKHM1 variants. monarchinitiative.org+1

Types

osteopetrosis is a group of diseases. doctors group them by inheritance and gene. the two big inheritance groups are autosomal dominant (usually milder) and autosomal recessive (often more severe). type 6 is one of the autosomal recessive subtypes and is specifically caused by PLEKHM1. within PLEKHM1 disease, doctors may describe the clinical? picture as mild, intermediate, or malignant? based on symptoms and complications, but genetically it is the same subtype (OPTB6). BioMed Central+2MedlinePlus+2

Causes

The single root cause is a pathogenic variant (mutation) in PLEKHM1, inherited in an autosomal recessive pattern (one faulty copy from each parent). PLEKHM1 is a scaffold protein that binds small GTPases like RAB7 and ARL8B and teams up with another protein DEF8. this complex moves and fuses late endosomes and lysosomes with the ruffled border of the osteoclast. that fusion is needed to pump acid (via V-ATPase) and to release enzymes (like cathepsin K) onto bone. without working PLEKHM1, the acid packets and enzymes never get to bone, so bone is not resorbed. PubMed+3PMC+3RUPress+3

in a single-gene disease like OPTB6, the cause is the PLEKHM1 variant. below are 20 mechanistic causes/contributors that explain how PLEKHM1 failure leads to the osteoclast problem and the clinical picture.

1. Loss-of-function PLEKHM1 variants (nonsense, frameshift, splice): these can truncate the protein and abolish function. PubMed

2. Missense variants in key domains (PH, RUN, LC3-interacting region): these can disrupt protein–protein binding needed for vesicle traffic. ScienceDirect

3. Failure to bind RAB7: PLEKHM1 is a RAB7 effector; impaired binding blocks late endosome–lysosome transport. RUPress

4. Failure to bind ARL8B: PLEKHM1 also binds ARL8B; loss compromises lysosome positioning toward the ruffled border. RUPress

5. DEF8 complex disruption: PLEKHM1–DEF8–RAB7 complex is crucial for lysosome movement; disruption halts cargo delivery. PMC

6. Blocked autophagosome–lysosome fusion: PLEKHM1 helps fusion; loss causes “traffic jams” of vesicles. ScienceDirect

7. Poor acidification at the ruffled border: if V-ATPase cannot be delivered, bone resorption stops. PMC

8. Reduced secretion of cathepsin K and other enzymes: the degradative enzymes fail to reach bone surface. PMC

9. Defective ruffled border formation: vesicle fusion drives the ruffled border; if fusion fails, the border is small or absent. PubMed

10. Secondary failure of bone remodeling: if osteoclasts cannot resorb, new bone is laid on old bone, creating dense but fragile bone. BioMed Central

11. Marrow space crowding: too much dense bone compresses marrow, causing anemia and low blood counts. BioMed Central

12. Cranial nerve tunnel narrowing: dense bone may narrow skull? foramina, leading to vision or hearing problems. BioMed Central

13. Dental eruption failure: osteoclasts help teeth erupt; if they fail, teeth may not erupt on time. BioMed Central

14. Susceptibility to osteomyelitis? of the jaw: sclerotic bone with poor blood flow is prone to infection? after dental issues. BioMed Central

15. Modifier genes and pathways (e.g., SNX10 pathway overlap): other vesicle-traffic genes can shape severity. ScienceDirect

16. Allelic heterogeneity: different PLEKHM1 variants can create mild or intermediate disease. PubMed

17. Compound heterozygosity: two different pathogenic variants from parents can combine to cause disease. BioMed Central

18. Consanguinity (inheritance context): increases likelihood of autosomal recessive conditions, including OPTB6. BioMed Central

19. Potential immune-signaling cross-talk (TRAFD1/FLN29 interacting with PLEKHM1): may modulate osteoclast function and phenotype. PLOS

20. Developmental timing effects: osteoclast dysfunction early in life can be worse; some PLEKHM1 cases improve with age. NCBI

Common symptoms and signs

1. Bone pain?: dense bone traps normal remodeling, causing pressure and pain?, especially in legs and back. BioMed Central

2. Fractures after minor injury: bones look hard but are brittle; small falls can cause breaks. MedlinePlus

3. Short stature or slowed growth: crowded marrow and abnormal bone modeling can slow normal growth. BioMed Central

4. Anemia (pallor, tiredness): reduced marrow space lowers red cell production. BioMed Central

5. Low platelets or white cells: crowding can also reduce platelets (bruising?) and neutrophils (infections). BioMed Central

6. Large liver? or spleen? (hepatosplenomegaly): the body tries to make blood cells outside the marrow. BioMed Central

7. Delayed tooth eruption and dental crowding: osteoclast failure delays tooth breakthrough; teeth can be misaligned. BioMed Central

8. Increased dental infections: dense jaw bone with poor flow raises infection risk. BioMed Central

9. Vision problems: narrowed optic canal can press the optic nerve?; vision may blur or decrease. BioMed Central

10. Hearing problems: dense skull can affect the auditory nerve or ossicles, causing hearing loss. BioMed Central

11. Frequent headaches: skull changes and sinus? blockage can cause head pain. BioMed Central

12. Nasal or sinus issues: thick bones can narrow sinuses?, leading to congestion or infections. BioMed Central

13. Limping or bowed legs: abnormal bone modeling changes limb shape and gait. BioMed Central

14. Low calcium symptoms in severe infant cases: twitching or seizures from hypocalcemia can happen in some osteopetrosis forms (rarer in mild PLEKHM1 cases). NCBI

15. Sometimes very mild or no symptoms: a few PLEKHM1 cases are subtle and may improve with age. NCBI

Diagnostic tests

A) Physical examination (bedside observations)

1. General growth check: height, weight, head size. delayed growth or large head can suggest osteopetrosis. BioMed Central

2. Pale skin and fatigue?: can suggest anemia from low marrow space. BioMed Central

3. Liver and spleen palpation: enlarged organs point to extra-medullary blood formation. BioMed Central

4. Neurologic cranial nerve exam: vision, eye movements, facial sensation, and hearing can be affected by narrowed skull canals. BioMed Central

5. Dental and jaw exam: delayed eruption, malocclusion, and tender jaw may be present. BioMed Central

B) Manual/clinical chair-side tests (simple office maneuvers)

6. Visual acuity? and color vision charts: quick screen for optic nerve compromise. BioMed Central

7. Hearing screening? (whisper, tuning fork): bedside test suggests if formal audiology is needed. BioMed Central

8. Gait assessment? and joint range tests: look for limping and mobility limits from bone shape changes. BioMed Central

9. Dental percussion and mobility checks: sensitive teeth or poor eruption guide dental imaging. BioMed Central

10. Spine and limb alignment check: inspect for bowing or scoliosis? from abnormal bone modeling. BioMed Central

C) Laboratory and pathological tests

11. Complete blood count? (CBC?): anemia, low platelets, or low white cells reflect marrow crowding. BioMed Central

12. Serum calcium, phosphate, alkaline phosphatase: helps gauge bone turnover and complications. BioMed Central

13. Bone turnover markers (e.g., TRAP5b, CTX): may show low resorption activity when osteoclasts fail. BioMed Central

14. Genetic testing for PLEKHM1 (targeted or gene panels for ARO): confirms the diagnosis and identifies the exact variant(s). Orpha.net+1

15. Peripheral smear and reticulocyte count: help assess marrow function and possible hemolysis or stress erythropoiesis. BioMed Central

D) Electrodiagnostic / neurophysiology

16. Visual evoked potentials (VEPs): measure optic nerve conduction; delay suggests optic canal compression. BioMed Central

17. Auditory brainstem response (ABR): tests hearing nerve pathways; abnormal results can reflect skull base narrowing. BioMed Central

18. Nerve conduction studies (in selected cases): look for secondary nerve compression effects in limbs. BioMed Central

E) Imaging tests

19. Skeletal survey (x-rays): shows “bone-in-bone,” diffuse sclerosis, and Erlenmeyer-flask-shaped femurs—classic osteopetrosis signs. BioMed Central

20. CT/MRI of skull base and spine: checks narrowing of optic canal, internal auditory canal, and neural foramina; MRI also assesses marrow space. BioMed Central

Non-pharmacological treatments (therapies & other care)

Below are practical, non-drug strategies commonly used across osteopetrosis (adapted to OPTB6). They aim to protect vision, hearing, growth, marrow health, teeth, and fracture risk. Evidence comes from rare-disease reviews and care overviews; individual plans should be tailored by specialists.

1. Multidisciplinary care & monitoring
   Regular follow-up with genetics, hematology, endocrinology/orthopedics, neurology/ophthalmology, and dentistry helps catch complications early—like marrow failure, cranial nerve compression (vision/hearing), fractures, and dental infections. Routine labs (blood counts, calcium, vitamin D), growth checks, and imaging guide decisions. Coordinated care is vital in rare bone disorders where severity varies by gene and child. BioMed Central+1

2. Fracture prevention & safe physical therapy
   Dense bones in osteopetrosis can still break easily. Home safety (fall proofing), supervised low-impact activity, physical therapy for muscle strength/balance, and avoiding high-impact sports reduce fracture risk. A PT familiar with bone fragility programs gentle strengthening while teaching safe transfers and mobility. BioMed Central

3. Vision surveillance & early referral
   Because narrowed skull openings can press on the optic nerves, scheduled eye exams (acuity, fundus, visual fields) are crucial. If vision drops or optic disc swelling appears, urgent neurosurgical/ophthalmic review is needed to consider decompression. BioMed Central

4. Hearing surveillance & support
   Conductive and/or sensorineural hearing loss can occur from nerve/bone issues. Early audiology testing, tympanometry, and timely hearing amplification or ENT procedures help development and communication. BioMed Central

5. Dental & maxillofacial care
   Tooth eruption problems, enamel defects, and infection risk are higher. Early dental referral, fluoride, meticulous oral hygiene, and pre-procedure planning reduce osteomyelitis risk, which is harder to treat in sclerotic bone. Dentists should use gentle technique and antibiotics when indicated. BioMed Central

6. Nutrition with adequate calcium & vitamin D (not excessive)
   Balanced intake supports bone health and growth, but mega-doses of calcium/vitamin D are not helpful unless deficient, and may worsen hypercalcemia risk. Dietitians individualize targets based on labs and growth. BioMed Central

7. Anemia management without drugs (supportive)
   When blood counts run low from narrow marrow spaces, supportive practices (infection prevention, timely vaccinations, nutrition, avoiding unnecessary blood loss) can help while clinicians decide on medical/surgical options. BioMed Central

8. Infection prevention & vaccination
   Crowded marrow and dental issues can raise infection risk. Staying current with routine vaccines, dental prophylaxis when appropriate, and early treatment of infections (sinus, dental, ear) is important. BioMed Central

9. School & developmental supports
   Children with visual/hearing challenges or frequent medical visits may need learning accommodations, mobility help, and speech/occupational therapies to keep development on track. BioMed Central

10. Genetic counseling for family planning
    OPTB6 is autosomal recessive. Genetic counseling explains carrier risks (25% affected risk when both parents are carriers), options for prenatal or preimplantation testing, and the range of severity. BioMed Central

Note: Some sources report mild courses in PLEKHM1 disease, sometimes improving with age; others describe more severe marrow issues—hence individualized monitoring. NCBI+1

Drug treatments

Only one medicine—interferon gamma-1b (ACTIMMUNE®)—has an FDA-approved indication directly related to osteopetrosis (specifically “severe, malignant osteopetrosis”). Other medications are supportive or used off-label to manage complications, guided by expert centers. I’ll clearly separate the FDA-approved option from supportive/off-label categories and cite FDA labels where relevant.

A) FDA-approved for osteopetrosis

1. Interferon gamma-1b (ACTIMMUNE®)
   Class & purpose. Cytokine (immune modulator). Indication (FDA): “Delaying time to disease progression in patients with severe, malignant osteopetrosis.” Used to improve bone resorption markers and reduce disease progression when transplant is not possible or as part of a broader plan in severe infantile disease. Dose & timing. Label dosing is typically subcutaneous three times weekly (dose varies by body surface area); clinicians adjust by age/weight and labs. Mechanism. Enhances macrophage/osteoclast activation and downstream antimicrobial/immune pathways that can secondarily improve bone resorption in osteoclast-poor function states. Side effects & monitoring. Fever, flu-like symptoms, elevated liver enzymes, neutropenia and thrombocytopenia (monitor counts), potential hepatic toxicity with accumulation—so periodic CBC and LFTs are recommended. The product also carried an FDA requirement for a treated-patient registry in severe malignant osteopetrosis. FDA Access Data+3FDA Access Data+3FDA Access Data+3

B) Common supportive/off-label medications used in osteopetrosis care (evidence from reviews; not FDA-approved specifically for OPTB6)

2. Calcitriol (active vitamin D)
   Class & purpose. Active vitamin D analog used to stimulate osteoclasts and manage calcium balance; historically tried in osteoclast dysfunction disorders. Use. Off-label in select cases; target is to carefully encourage bone turnover while avoiding hypercalcemia. Mechanism. Promotes osteoclast differentiation indirectly through RANKL signaling and improves intestinal calcium absorption. Risks. Hypercalcemia and hypercalciuria; thus tight lab monitoring is essential. (Note: FDA label indications are for hypocalcemia and related conditions—not osteopetrosis.) BioMed Central

3. Prednisone (short courses in select scenarios)
   Purpose. Sometimes used short-term to reduce inflammation around compressed nerves or to manage certain marrow/immune complications; this is not standard disease-modifying therapy for OPTB6. Mechanism. Anti-inflammatory and lympholytic effects. Risks. Growth suppression, infection risk, glucose changes—so specialist oversight is needed. BioMed Central

4. Hematopoietic growth factors (e.g., EPO for anemia, G-CSF for neutropenia)
   Purpose. Support blood counts when marrow is crowded. Mechanism. Stimulate red cell or neutrophil production. Note. These address complications rather than the underlying bone defect; hematology teams weigh benefits/risks case by case. BioMed Central

5. Analgesics for fracture/bone pain (acetaminophen ± cautious use of others)
   Purpose. Pain control around fractures or orthopedic interventions. Note. Choice must account for liver/kidney function and bleeding risk if platelets are low. BioMed Central

Why not bisphosphonates? In classic osteoporosis, they slow bone breakdown; in osteopetrosis the issue is too little resorption—not too much—so bisphosphonates are generally not helpful and can worsen problems. Management focuses on restoring or supporting osteoclast function, protecting nerves, and treating complications. BioMed Central

Dietary molecular supplements

Evidence in OPTB6 is limited; supplements are aimed at general bone/marrow health or deficiency correction. Always check labs and specialist advice to avoid over- or under-supplementation.

1. Physiologic Vitamin D (cholecalciferol) to sufficiency
   Maintaining normal 25-OH vitamin D helps bone mineral balance and muscle function; avoid deficiency and also avoid excess. Dosing is individualized to reach normal serum levels. BioMed Central

2. Calcium to the daily recommended intake (not high-dose unless deficient)
   The goal is a balanced diet meeting age-appropriate needs; unnecessary high doses can risk hypercalcemia, particularly if calcitriol is used. BioMed Central

3. Protein-adequate nutrition
   Adequate protein supports growth, fracture healing, and marrow health. Dietitian guidance tailors needs to age, growth, and clinical status. BioMed Central

4. Iron only if iron-deficient
   Addressing true iron deficiency assists red cell production, but routine iron without deficiency is not recommended. Hematology guides decisions. BioMed Central

5. Folate/B12 if deficient
   Correcting megaloblastic contributors to anemia improves overall marrow output in a setting where marrow space is limited. Screen before supplementing. BioMed Central

6. Omega-3 fatty acids (dietary sources)
   General anti-inflammatory effects may help comfort and cardiovascular health; evidence is supportive/adjunctive, not disease-modifying. BioMed Central

7. Magnesium to sufficiency
   Normal magnesium supports bone and neuromuscular function; supplement if low, guided by labs. BioMed Central

8. Zinc to sufficiency
   Zinc participates in growth and immune function; correct deficiency if present, avoiding excess. BioMed Central

9. Balanced calories for catch-up growth
   Under-nutrition can worsen bone and immune outcomes; dietetic plans optimize calories without overfeeding. BioMed Central

10. Hydration & fiber
    Useful for constipation from reduced mobility or analgesics, supporting overall well-being during long-term care. BioMed Central

Immunity-booster / regenerative / stem-cell therapies

In osteopetrosis due to osteoclast defects, the only curative strategy for severe infantile forms across many genes is often hematopoietic stem cell transplantation (HSCT)—because osteoclasts come from marrow precursors. Whether HSCT is appropriate in PLEKHM1-related disease depends on severity and expert center judgment.

1. Hematopoietic stem cell transplantation (HSCT)
   Function. Replaces defective hematopoietic precursors, allowing donor-derived osteoclasts to resorb bone. Dose/approach. Conditioning and donor selection per transplant protocols. Mechanism. Donor osteoclasts correct the resorption defect (when the defect is hematopoietic). Note. Benefit depends on gene and disease severity; OPTB6 can be mild in some, so indications must be individualized at expert centers. BioMed Central

2. Interferon gamma-1b (see above; immune modulation)
   Although not a “stem-cell drug,” IFN-γ1b is the only U.S. FDA-approved medicine for severe malignant osteopetrosis and can be used in severe courses when transplant is not an option or as part of protocolized care. FDA Access Data

3. Emerging gene-targeted concepts (research stage)
   Basic science continues to clarify vesicular trafficking defects (e.g., PLEKHM1/SNX10), suggesting future targeted therapies; today, these remain experimental and not clinically available. repository.uantwerpen.be+1

Surgeries & procedures

1. Optic nerve decompression
   If optic nerves are compressed in their bony canals causing vision loss, surgeons may remove bone around the canal to relieve pressure and preserve sight. Decision is urgent and based on neuro-ophthalmic exams and imaging. BioMed Central

2. Orthopedic fracture care & corrective osteotomies
   Because bones are dense yet brittle, fractures are treated with careful fixation; deformities from abnormal growth may need osteotomies to restore alignment and function. Surgeons plan meticulously due to hard, sclerotic bone and healing considerations. BioMed Central

3. Dental/maxillofacial procedures with infection-control planning
   Impacted teeth, abscesses, or osteomyelitis risk require coordinated dental–surgical care, often with antibiotics and gentle technique to lower complication risk in sclerotic jaw bones. BioMed Central

4. ENT procedures for hearing issues
   Selected middle-ear procedures or ventilation tubes may improve hearing where conductive issues exist, paired with audiology support. BioMed Central

5. Neurosurgical decompression for other cranial nerves
   If facial palsy or other nerve deficits occur from narrowed foramina, decompression can be considered. Decisions are individualized in expert centers. BioMed Central

Prevention

While you cannot “prevent” a genetic disease, you can reduce complications:

1. Keep regular specialty follow-ups and labs. BioMed Central

2. Use fall-prevention strategies and safe exercise. BioMed Central

3. Maintain dental hygiene and early dental care. BioMed Central

4. Stay up-to-date on vaccines. BioMed Central

5. Seek early care for infections (sinus, ear, dental). BioMed Central

6. Balanced nutrition to targets; avoid extremes. BioMed Central

7. Hearing & vision screening as scheduled. BioMed Central

8. Safe home environment (remove trip hazards). BioMed Central

9. Medication adherence/monitoring when used (e.g., IFN-γ1b). FDA Access Data

10. Genetic counseling for family planning. BioMed Central

When to see a doctor (red flags)

Call or see your specialist promptly for: new vision loss, double vision, hearing drop, frequent infections, fever, unusual bruising/bleeding, severe bone pain or suspected fracture, growth faltering, seizures (can occur with calcium issues), persistent headaches, or dental pain/swelling. These can signal nerve compression, marrow problems, fractures, calcium imbalance, or jaw infection—all time-sensitive in osteopetrosis. BioMed Central

What to eat & what to avoid

Eat: balanced meals with adequate protein; natural sources of calcium and vitamin D; fruits/vegetables (fiber); whole grains; healthy fats. Avoid: excessive calcium or vitamin D supplements unless your labs are low; very high-salt ultra-processed foods (fluid retention/blood pressure); sugary drinks (excess calories); alcohol (adolescents/adults) that impairs bone health; and fad supplements without clinician approval. Hydration and fiber help if pain medicines cause constipation. Dietitians personalize plans using labs and growth curves. BioMed Central

FAQs

1) Is OPTB6 always severe?
No. Reports range from mild courses that may improve with age to more serious cases with low blood counts and enlarged spleen/liver, so close monitoring is essential. NCBI+1

2) How is it confirmed?
Clinical features plus radiographs showing dense bones and genetic testing confirming biallelic PLEKHM1 variants. BioMed Central

3) Can medications cure it?
There’s no pill that cures OPTB6. Interferon gamma-1b is the only FDA-approved medicine for severe malignant osteopetrosis to delay progression; other drugs are supportive/off-label. FDA Access Data

4) Is HSCT an option?
Possibly—depending on severity and gene biology, because osteoclasts arise from marrow. Decision requires an experienced transplant center. BioMed Central

5) What symptoms should families watch for daily?
Vision or hearing changes, frequent infections, easy bruising, bone pain, fractures, dental pain. Report promptly. BioMed Central

6) What is the gene doing in simple words?
PLEKHM1 helps osteoclasts move packets inside the cell to break down old bone. If it’s broken, bone builds up and marrow spaces narrow. repository.uantwerpen.be

7) Why are teeth and jaws a focus?
Dense jaw bones and tooth eruption problems raise infection and osteomyelitis risks; preventative dental care lowers complications. BioMed Central

8) Are there research advances?
Yes—better gene discovery and pathophysiology (vesicle trafficking) are guiding future targeted therapies, but these are not yet available. repository.uantwerpen.be+1

9) What about CLCN7 or TCIRG1 I’ve read about?
They cause other osteopetrosis subtypes. Care principles overlap, but gene-specific features and HSCT considerations can differ. NCBI+1

10) Is this inherited?
Yes—autosomal recessive: parents are usually healthy carriers; each pregnancy has a 25% chance to be affected. BioMed Central

11) Can bones be both hard and fragile?
Yes—high mineral density with abnormal micro-architecture makes them brittle and prone to fractures. BioMed Central

12) Will my child’s height be affected?
Growth failure can occur in more severe forms; nutrition, fracture prevention, and timely interventions support better growth. BioMed Central

13) Is vision loss permanent?
Compression can cause permanent damage if untreated; early detection and surgical decompression may preserve function. BioMed Central

14) Who should coordinate care?
A center experienced with rare skeletal dysplasias—often pediatric genetics with hematology, endocrinology/orthopedics, neurology/ophthalmology, ENT, and dentistry. BioMed Central

15) Where can I read more or get help?
See GeneReviews/rare-disease summaries and GARD; FDA pages detail IFN-γ1b labeling and orphan approval history. FDA Access Data+4NCBI+4BioMed Central+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.